Market Overview

Why Vertex's Stock Is Trading Higher Today


Vertex Pharmaceuticals (NASDAQ: VRTX) shares are trading higher after Argus Research maintained a Buy rating on the stock and raised its price target from $270 to $320.

Vertex Pharmaceuticals discovers and develops small-molecule drugs. The company’s key drugs include Kalydeco, Orkambi, Symdeko and Trikafta.

The health care sector has seen an increase in volatility as companies race to satisfy the increased demand caused by the coronavirus.

Vertex shares were trading higher by 3.92% at $287.86 at time of publication on Friday. The stock has a 52-week high of $288.52 and a 52-week low of $165.23.

Latest Ratings for VRTX

Nov 2020BernsteinInitiates Coverage OnOutperform
Oct 2020Credit SuisseMaintainsOutperform
Oct 2020SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for VRTX
View the Latest Analyst Ratings


Related Articles (VRTX)

View Comments and Join the Discussion!

Posted-In: why it's movingPrice Target Analyst Ratings Movers Trading Ideas

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at